Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors

Documenti analoghi

• Long term follow up of treatment with ibrutinib and rituximab (IR) in patients with high-risk Chronic Lymphocytic Leukemia (CLL)
  di: Jain, Preetesh, et al.
  Pubblicazione: (2016)
• Long-term Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) who Discontinue Ibrutinib
  di: Jain, Preetesh, et al.
  Pubblicazione: (2017)
• Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy
  di: Schliffke, Simon, et al.
  Pubblicazione: (2018)
• Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
  di: Jain, Preetesh, et al.
  Pubblicazione: (2015)
• Complex Karyotype is a Stronger Predictor than Del(17p) for Inferior Outcome in Relapsed or Refractory CLL Patients Treated with Ibrutinib-Based Regimens
  di: Thompson, Philip A., et al.
  Pubblicazione: (2015)